A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

Abstract A neoadjuvant immunotherapy platform clinical trial allows for rapid evaluation of treatment-related changes in tumors and identifying targets to optimize treatment responses. We enrolled patients with resectable pancreatic adenocarcinoma into such a platform trial (NCT02451982) to receive...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Thatcher Heumann, Carol Judkins, Keyu Li, Su Jin Lim, Jessica Hoare, Rose Parkinson, Haihui Cao, Tengyi Zhang, Jessica Gai, Betul Celiker, Qingfeng Zhu, Thomas McPhaul, Jennifer Durham, Katrina Purtell, Rachel Klein, Daniel Laheru, Ana De Jesus-Acosta, Dung T. Le, Amol Narang, Robert Anders, Richard Burkhart, William Burns, Kevin Soares, Christopher Wolfgang, Elizabeth Thompson, Elizabeth Jaffee, Hao Wang, Jin He, Lei Zheng
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Nature Portfolio 2023-06-01
Sarja:	Nature Communications
Linkit:	https://doi.org/10.1038/s41467-023-39196-9
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!